Chemo4MetPanc: A phase II study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment naïve pancreas adenocarcinoma (PDAC).

Ilenia Pellicciotta,Emily Linda Alouani,Alexander G. Raufi,Samuel M Pan,Jianhua Hu,Gulam Abbas Manji

Chemo4MetPanc: A phase II study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment naïve pancreas adenocarcinoma (PDAC).

2021

Ilenia Pellicciotta
Emily Linda Alouani
Alexander G. Raufi
Samuel M Pan
Jianhua Hu
Gulam Abbas Manji

TPS454Background: Pancreas adenocarcinoma (PDAC) is an aggressive cancer projected to be the second leading cause of cancer-related death in the United States by 2030 for which improved treatment o...

Keywords:

Blockade
Receptor
Gemcitabine
Pancreas adenocarcinoma
Chemokine
Phases of clinical research
Medicine
combination chemotherapy
Cancer research
Immune checkpoint

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations